Clinical trials: Pancreatic Disorders
Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC)
Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors
The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics (PK) of escalating doses of RMC-6291 (KRAS G12C(ON) inhibitor) monotherapy in adult subjects with advanced solid tumors and to identify the…
- Conditions
- Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma, Advanced Solid Tumor
- Trial name
- NCT05462717
- Testing
- RMC-6291
- Where
- 64 sites in United States, Australia and 11 more
- Volunteers
- 222 people
- Sponsor
- Revolution Medicines, Inc.
Pancreatic Cancer
A Phase II Trial of TPI 287 in Patients Advanced, Unresectable Pancreatic Cancer
The primary objective of the study is to assess the activity of TPI 287 as single agent therapy for patients with advanced, unresectable pancreatic cancer after failure of gemcitabine-containing therapy.
- Trial name
- NCT00553813
- Testing
- TPI 287
- Where
- 4 sites in United States, Spain
- Volunteers
- 23 people
- Sponsor
- Cortice Biosciences, Inc.
Type1 Diabetes Mellitus
Insulet Artificial Pancreas Free-Living IDE3
Subjects will undergo a 7±1 day outpatient, standard therapy phase during which sensor and insulin data will be collected. Subjects or their caregivers will manage their diabetes at home per their usual routine using the study…
- Trial name
- NCT03216460
- Testing
- Insulet automated glucose control system
- Where
- 3 sites in United States
- Volunteers
- 120 people
- Sponsor
- Insulet Corporation
Asthma
Single Dose Study to Evaluate the Safety, and Efficacy of S-1226 (8%) in Subjects With Mild Atopic Asthma
Evaluate the safety and tolerability of a single dose of S-1226 (8%) in subjects with mild atopic asthma.
- Trial name
- S-1226(8%) (NCT02334553)
- Testing
- S1226(8%)
- Where
- Canada
- Volunteers
- 12 people
- Sponsor
- SolAeroMed Inc.
Locally Advanced or Metastatic Solid Tumors, Colorectal Cancer
A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors
This is an open-label, multi-center, phase I study to evaluate the safety, tolerability, efficacy, and pharmacokinetics of MRG007 (ARR-217) in patients with unresectable locally advanced or metastatic solid tumors.
- Conditions
- Locally Advanced or Metastatic Solid Tumors, Colorectal Cancer, Gastric Cancer, Pancreatic Cancer
- Trial name
- NCT07066657
- Testing
- MRG007, MRG007 and Bevacizumab
- Where
- 21 sites in United States, China
- Volunteers
- 572 people
- Sponsor
- ArriVent BioPharma, Inc.
KRAS Altered Advanced or Metastatic Solid Tumors
AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid Tumors
The purpose of this first-in-human study is to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of AMG 410 when administered alone or in combination with other agents in…
- Trial name
- NCT07094113
- Testing
- AMG 410, Pembrolizumab, Panitumumab
- Where
- 39 sites in United States, Australia and 12 more
- Volunteers
- 434 people
- Sponsor
- Amgen
Solid Tumor, Adult, Epithelial Ovarian Cancer
Study of CBX-12 in Subjects With Advanced or Metastatic Refractory Solid Tumors
This is a first-in-human, Phase 1/2 open-label, multicenter, dose-escalation, safety, pharmacokinetics (PK), and biomarker study of CBX-12 in subjects with advanced or metastatic refractory solid tumors.
- Conditions
- Solid Tumor, Adult, Epithelial Ovarian Cancer, Small Cell Lung Carcinoma, Breast Cancer
- Trial name
- NCT04902872
- Testing
- CBX-12
- Where
- 4 sites in United States
- Volunteers
- 69 people
- Sponsor
- Cybrexa Therapeutics
Pancreatic Cancer
Liposomal Irinotecan in Combination With Oxaliplatin and S-1 Versus Gemcitabine Combined With Capecitabine as Postoperative Adjuvant Therapy for Pancreatic Cancer
This study will evaluate the efficacy and safety of adjuvant therapy with liposomal irinotecan in combination with oxaliplatin, and S-1 compared with capecitabine combined with capecitabine in participants with pancreatic ductal…
- Trial name
- NCT06571461
- Testing
- Liposomal Irinotecan, Oxaliplatin, S-1
- Volunteers
- 408 people
- Sponsor
- CSPC Ouyi Pharmaceutical Co., Ltd.
Pancreatic Cancer Metastatic
A Study of Narmafotinib Given in Combination With Modified FOLFIRINOX in Patients With Metastatic Pancreatic Cancer
This study is testing narmafotinib, a type of drug called a focal adhesion kinase (FAK) inhibitor, when it is given in combination with 4 chemotherapy drugs in a regimen called FOLFIRINOX, to patients who have pancreatic cancer…
- Trial name
- NCT07026279
- Testing
- narmafotinib ascending doses, narmafotinib dose comparison
- Where
- 2 sites in Australia
- Volunteers
- 67 people
- Sponsor
- Amplia Therapeutics Limited
Non Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma
This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid Tumors
This is a phase 1 dose escalation trial of ZM008, an anti-LLT1 antibody as a single agent followed by combination with Toripalimab in patients with advanced solid tumors who have exhausted all standard therapy available or are…
- Conditions
- Non Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Pancreas Adenocarcinoma, Biliary Tract Cancer
- Trial name
- NCT06451497
- Testing
- ZM008
- Where
- 3 sites in United States
- Volunteers
- 100 people
- Sponsor
- Zumutor Biologics Inc.
Gastric/Gastroesophageal Junction Adenocarcinoma, Metastatic Colorectal Cancer (CRC)
A Phase II Clinical Study Evaluating SSGJ-706 in Combination Therapy for Advanced Gastrointestinal Cancers
This study is a multicenter, open-label, phase II clinical trial evaluating the combination of SSGJ-706 with standard therapy for advanced gastrointestinal tumors.
- Conditions
- Gastric/Gastroesophageal Junction Adenocarcinoma, Metastatic Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC), Oesophageal Cancer
- Trial name
- NCT07233850
- Testing
- SSGJ-706+XELOX, SSGJ-706+Bevacizumab+XELOX, SSGJ-706+AG
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Shenyang Sunshine Pharmaceutical Co., LTD.
Advanced Ovarian Carcinoma, Advanced Renal Cell Carcinoma
First-in-human Phase I Study to Evaluate Safety, Tolerability and Antineoplastic Activity of OATD-02 in Patients With Selected Advanced and/or Metastatic Solid Tumours
The goal of this clinical trial is to learn if the OATD-02 administration (orally) in monotherapy is safe and has the pharmacodynamic potential to restore and enhance tumour responses to immunotherapy through increased arginine…
- Conditions
- Advanced Ovarian Carcinoma, Advanced Renal Cell Carcinoma, Advanced Pancreatic Carcinoma, Advanced Colorectal Carcinoma
- Trial name
- NCT05759923
- Testing
- OATD-02
- Where
- 3 sites in Poland
- Volunteers
- 40 people
- Sponsor
- Molecure S.A.
Chronic Rhinosinusitis, Cystic Fibrosis
Efficacy of Nasal Irrigation With Respimer® Netiflow® vs Saline Among Patients With Cystic Fibrosis and Chronic Rhinosinusitis
Prospective, randomized, cross-over, multicenter, trial comparing the efficacy and tolerability of nasal irrigation with Respimer® mineral salts solution versus saline solution both administered with Respimer® Netiflow® medical…
- Trial name
- Respire (NCT03145051)
- Testing
- Saline solution, Respimer Netiflow
- Where
- France
- Volunteers
- 50 people
- Sponsor
- Laboratoire de la Mer
Cystic Fibrosis
A Study to Investigate the Safety and Tolerability of Single and Multiple Ascending Doses of KIT2014 in Healthy Subjects
This is the first-in-human study with KIT2014 designed to provide safety, tolerability and pharmacokinetic data in healthy volunteers.
- Trial name
- NCT06659757
- Testing
- KIT2014
- Where
- Australia
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Kither Biotech Srl
Non Small Cell Lung Cancer, Medullary Thyroid Cancer
Expanded Access for the Treatment of Cancers With Rearranged During Transfection (RET) Activation
Expanded access for participants with cancer with RET activation who are ineligible for an ongoing selpercatinib (also known as LOXO-292) clinical trial or have other considerations that prevent access to selpercatinib through an…
- Conditions
- Non Small Cell Lung Cancer, Medullary Thyroid Cancer, Colon Cancer, Breast Cancer
- Trial name
- NCT03906331
- Testing
- Selpercatinib
- Where
- 64 sites in United States, Australia and 11 more
- Sponsor
- Eli Lilly and Company
Pancreatic Adenocarcinoma, Pancreatic Cancer
AdV-tk Therapy With Surgery and Chemoradiation for Pancreas Cancer (PaTK01)
The purpose of this Phase 1 study is to evaluate the safety and potential efficacy of Gene Mediated Cytotoxic Immunotherapy for pancreatic cancer.
- Trial name
- PaTK01 (NCT00638612)
- Testing
- AdV-tk, Valacyclovir
- Where
- 3 sites in United States
- Volunteers
- 27 people
- Sponsor
- Candel Therapeutics, Inc.
Ovarian Neoplasms, Endometrial Neoplasms
A Study of Sofe-M in Participants With Selected Advanced Solid Tumors
The purpose of this study is to find out whether the study drug, Sofetabart Mipitecan (LY4170156), is safe, tolerable and effective in participants with advanced solid tumors.
- Conditions
- Ovarian Neoplasms, Endometrial Neoplasms, Uterine Cervical Neoplasms, Carcinoma, Non-Small-Cell Lung
- Trial name
- NCT06400472
- Testing
- Sofe-M, bevacizumab, carboplatin
- Where
- 25 sites in United States, Australia and 5 more
- Volunteers
- 575 people
- Sponsor
- Eli Lilly and Company
Cystic Fibrosis
A Study Evaluating the Safety of VX-152 Combination Therapy in Adults With Cystic Fibrosis
This is a Phase 2, randomized, double blind, placebo and active-controlled, parallel group, multicenter study designed to evaluate the safety and tolerability of VX-152 in Triple Combination (TC) with tezacaftor (TEZ; VX-661) and…
- Trial name
- NCT02951195
- Testing
- VX-152, TEZ/IVA, IVA
- Where
- 16 sites in United States
- Volunteers
- 80 people
- Sponsor
- Vertex Pharmaceuticals Incorporated
Cancer, Melanoma
ENB003 Plus Pembrolizumab Phase 1b/2a in Solid Tumors
First-in Human study evaluating the safety, tolerability and efficacy of ENB003 in combination with Pembrolizumab in solid tumors. The study is separated into two parts.
- Conditions
- Cancer, Melanoma, Ovary Cancer, Pancreatic Cancer
- Trial name
- NCT04205227
- Testing
- ENB003, Pembrolizumab
- Where
- 5 sites in United States, Australia
- Volunteers
- 137 people
- Sponsor
- ENB Therapeutics, Inc
Pancreatic Cancer, Pancreatic Carcinoma Non-resectable
Immunotherapy and SBRT Study in Borderline Resectable Pancreatic Cancer
Unfortunately, despite the best clinical efforts and breakthroughs in biotechnology, most patients diagnosed with pancreatic cancer continue to die from the rapid progression of their disease.
- Trial name
- NCT02405585
- Testing
- mFOLFIRINOX, Algenpantucel-L Immunotherapy, SBRT
- Where
- 4 sites in United States
- Volunteers
- 10 people
- Sponsor
- NewLink Genetics Corporation
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.